pharmacokinetics, pharmacodynamics, safety and tolerability ofNN2211, a new long-acting GLP-1 derivative, in healthy men. Dia-betologia 45:195–202 33.Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L, LEAD-4 Study Investigators 2009 Efficacy and safety of the human glucagon-like peptide-1 analogliraglutide in combination with metformin and thiazolidinedione inpatients with type 2 diabetes (LEAD-4 Met /H11001TZD). Diabetes Care 32:1224–1230 34.Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo ´ R, Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met /H11545SU Study Group 2009 Liraglutide vs insulin glargine and placebo in combination with metformin andsulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met /H11001SU): a randomised controlled trial. Diabetologia 52:2046–2055 35.Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Du ¨ ring M, Mattheews DR, LEAD-2 Study Group